Partner with Tatva Pharma: innovate and grow
At Tatva Pharma, we believe in the power of collaboration to transform injectable medicines. We're actively seeking strategic partners who share our vision for intelligent reformulation, disciplined IP strategy, and global scalability. Discover how we can achieve exceptional outcomes together, reducing healthcare friction and improving patient outcomes across the UK and beyond.
Our ideal partners
Tatva Pharma is built on a foundation of collaboration. We are intentionally looking to team up with organisations and individuals whose expertise complements our innovative formulation platform. We value technical depth, regulatory credibility, and reliability in all our collaborations, fostering a partnership approach that delivers impactful results.
Licensing & co-development partners
Mid-size and specialty pharma companies seeking differentiated injectable assets without discovery risk. You bring regulatory execution, commercial scale, and market access; we bring protected, development-ready IP.
CROs & CDMOs
Specialist formulation labs, sterile manufacturing facilities, and analytical experts capable of executing complex injectable development to GMP standards. We value technical depth, regulatory credibility, and reliability.
Talented scientists & digital innovators
Formulation scientists, regulatory thinkers, and data specialists passionate about building practical, protectable innovation, not speculative research. Join us in shaping the future of injectable medicines.
Why partner with Tatva Pharma?
Partnering with Tatva means accessing de-risked, intelligently engineered injectable innovation without the burden of discovery-stage exposure. Our approach is designed for clarity, efficiency, and sustainable value creation, anchored by robust UK governance and regulatory alignment.
De-risked innovation & clear ip
Our formulations are designed around existing IP from the outset, providing patent-smart, freedom-to-operate–clear assets. Partners receive differentiated, defensible injectable platforms, not litigation exposure. This capital-efficient model absorbs early design, allowing partners to step in at defined value inflection points with clearer regulatory pathways and data-backed positioning. Our UK-anchored governance ensures robust IP ownership and regulatory strategy.
Achieve shared success
Together with our partners, we aim to deliver smarter injectables to patients, transforming proven medicines into safer, longer-acting, and easier-to-administer formats that genuinely improve adherence and tolerability. We strive to reduce healthcare friction by shortening infusion times and lowering medication-error risk, accelerate time to market through combined expertise, and create defensible, scalable value, establishing a repeatable innovation engine where each success funds the next. This generates high-margin, scalable opportunities across multiple territories.
